Join us for an informative webinar brought to you by Takeda on "Liver Cirrhosis: Current Status & Clinical Use of Albumin in Decompensated Cirrhosis." This engaging session will provide a comprehensive overview of liver cirrhosis, including its current status, challenges, and the vital role of albumin in managing decompensated cirrhosis. Led by esteemed experts in the field, this webinar aims to enhance your understanding of liver cirrhosis and its clinical management, particularly the use of albumin as a valuable therapeutic option.

Albumin in Decompensated Liver Cirrhosis

ACLF (acute-on-chronic liver failure) is a poorly characterised disease typified by fast clinical deterioration in chronic liver disease patients. High short-term morbidity, death, and healthcare resource utilisation are among the consequences. International hepatology societies have proposed heterogeneous definitions, diagnostic criteria, and treatment guidelines. Takeda brings to you an informative webinar about the latest APASL 2023 Updates with eminent speakers like Dr. Naveen Polavarapu, Dr. Anand V. Kulkarni, Dr. Arun Kumar Venuthurimilli, Dr. Charles Panackel and Dr. Madhu Sasidharan.

Acute-on-Chronic Liver failure: APASL 2023 Updates

Senior Consultant & Director, Critical Care Hepatology,  AIG Hospitals, Hyderabad; Ranked as world’s top 2% most-cited researchers with 150+ PubMed-indexed publications, Expertise in Viral Hepatitis, Alcohol-associated hepatitis, ACLF, HCC, and LDLT.

Chronic Hepatitis B (HBV) management remains a dynamic tightrope walk, where meeting treatment cessation criteria is only half the battle. In this 1st episode of ENHANCE, a case-based learning initiative by Viatris, we delve into the sharp realities of HBV management, viral reactivation, and the silent progression toward Hepatocellular Carcinoma (HCC). Led by renowned Moderator Dr. Yogesh Batra, this interactive episode features two complex, real-world case presentations by leading experts Dr. Akash Shukla and Dr. Anand Kulkarni. Together they will dissect the clinical nuances of viral rebounds, surveillance pitfalls, and the critical role of aggressive tumor biomarkers like PIVKA-II. 

Dr. Anand Kulkarni

3

1.2k

15.4k

4.5

Upcoming Sessions

Sessions Taken

700

4.6

1.2k

4.5